Table 2.
Impact of the clinical-demographic, nutritional and genetic factors on the subjective global assessment (SGA) score.
| Variable | SGA | ||||||
|---|---|---|---|---|---|---|---|
| A | B or C |
p OR [95%CI] |
A or B | C |
p OR [95%CI] |
||
| Gender | Male | 11 (18.64%) | 48 (81.36%) | 0.1418 | 39 (66.10%) | 20 (33.90%) | 0.3907 |
| Female | 4 (40.00%) | 6 (60.00%) | 0.34 [0.08–1.43] | 8 (80.00%) | 2 (20.00%) | 0.49 [0.09–2.51] | |
| Age (years) | ≥65 | 9 (31.03%) | 20 (68.67%) | 0.1173 | 18 (62.07%) | 11 (37.93%) | 0.3603 |
| <65 | 6 (15.00%) | 34 (85.00%) | 2.55 [0.79–8.23] | 29 (72.50%) | 11 (27.50%) | 0.62 [0.22–1.72] | |
| Histopathological diagnosis | Squamous-cell carcinoma | 12 (18.75%) | 52 (81.25%) | 0.0530 | 42 (65.63%) | 22 (37.37%) | 0.2401 |
| Others | 3 (60.00%) | 2 (40.00%) | 0.15 [0.02–1.02] | 5 (100.00%) | - | 0.17 [0.01–3.25] | |
| Tumor location | Oropharyngeal | 11 (37.93%) | 18 (62.07%) | 0.0089 * | 20 (68.97%) | 9 (31.03%) | 0.8974 |
| Others | 4 (10.00%) | 36 (90.00%) | 5.50 [1.53–19.71] | 27 (67.50%) | 13 (32.50%) | 1.07 [0.38–2.99] | |
| Larynx | 4 (11.11%) | 32 (88.89%) | 0.0319 * | 24 (66.67%) | 12 (33.33%) | 0.7874 | |
| Others | 11 (33.33%) | 22 (66.67%) | 0.25 [0.07–0.89] | 23 (69.70%) | 10 (30.30%) | 0.87 [0.31–2.40] | |
| T stage | T1–3 | 15 (41.67%) | 21 (58.33%) | 0.0080 * | 30 (83.33%) | 6 (16.67%) | 0.0063 * |
| T4 | - | 33 (100.00%) | 48.30 [2.75–850.05] | 17 (51.52%) | 16 (48.48%) | 4.71 [1.55–14.29] | |
| N stage | N0 | 8 (34.78%) | 15 (65.22%) | 0.0696 | 19 (82.61%) | 4 (17.39%) | 0.0753 |
| N1–3 | 7 (15.22%) | 39 (84.78%) | 2.97 [0.92–9.63] | 28 (60.87%) | 18 (39.13%) | 3.05 [0.89–10.44] | |
| M stage | M0 | 15 (22.06%) | 53 (77.94%) | 0.9326 | 47 (69.12%) | 21 30.88%) | 0.2527 |
| M1 | - | 1 (100.00%) | 0.87 [0.03–22.42] | - | 1 (100.00%) | 6.63 [0.26–169.40] | |
| Disease stage | III | 7 (35.00%) | 13 (65.00%) | 0.0948 | 16 (80.00%) | 4 (20.00%) | 0.1829 |
| IVA-IVC | 8 (16.33%) | 41 (83.67%) | 2.76 [0.84–9.08] | 31 (63.26%) | 18 (36.73%) | 2.32 [0.67–8.03] | |
| Performance status (PS) | ≤1 | 12 (20.34%) | 47 (79.66%) | 0.4967 | 42 (71.19%) | 17 (28.81%) | 0.1929 |
| >1 | 3 (30.00%) | 7 (70.00%) | 0.60 [0.13–2,65] | 5 (50.00%) | 5 (50.00%) | 2.47 [0.63–9.64] | |
| Alcohol consumption | Yes | 5 (17.24%) | 24 (82.76%) | 0.4428 | 16 (55.17%) | 13 (44.83%) | 0.0530 |
| No | 10 (25.00%) | 30 (75.00%) | 0.62 [0.19–2.08] | 31 (77.50%) | 9 (22.50%) | 0.36 [0.13–1.01] | |
| Smoking status | Smoker | 8 (15.69%) | 43 (84.31%) | 0.0466 * | 32 (62.75%) | 19 (37.25%) | 0.1178 |
| Non-smoker | 7 (38.89%) | 11 (61.11%) | 2.29 [0.09–0.98] | 15 (83.33%) | 3 (16.67%) | 0.34 [0.09–1.32] | |
| Concurrent C-RT | Yes | 8 (28.57%) | 20 (71.43%) | 0.4967 | 19 (67.86%) | 9 (32.14%) | 0.9696 |
| No | 7 (17.07%) | 34 (82.93%) | 1.94 [0.61–6.17] | 28 (68.29%) | 13 (31.71%) | 0.98 [0.35–2.75] | |
| ITGAM genotype | AA | 11 (37.93%) | 18 (62.07%) | 0.0089 * | 28 (96.55%) | 1 (3.45%) | 0.0013 * |
| GA or GG | 4 (10.00%) | 36 (90.00%) | 5.50 [1.53–19.71] | 19 (47.50%) | 21 (52.50%) | 30.95 [3.83–249.96] | |
| GG | - | 6 (100.00%) | 0.3412 | 1 (16.67%) | 5 (83.33%) | 0.0213 * | |
| AA or GA | 15 (23.81%) | 48 (76.19%) | 0.24 [0.01–4.52] | 46 (73.02%) | 17 (26.98%) | 0.07 [0.01–0.68] | |
*-statistically significant results.